JP2000511042A - Il−13受容体特異的キメラタンパク質およびその用途 - Google Patents
Il−13受容体特異的キメラタンパク質およびその用途Info
- Publication number
- JP2000511042A JP2000511042A JP08528499A JP52849996A JP2000511042A JP 2000511042 A JP2000511042 A JP 2000511042A JP 08528499 A JP08528499 A JP 08528499A JP 52849996 A JP52849996 A JP 52849996A JP 2000511042 A JP2000511042 A JP 2000511042A
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- cells
- receptor
- pe38qqr
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.IL−13受容体を有する腫瘍細胞にエフェクター分子を特異的にデリバリー する方法であって: IL−13受容体と特異的に結合する標的指向分子に結合された前記エフェクター 分子を含有するキメラ分子を提供し;そして 前記腫瘍を前記キメラ分子と接触させる、 ことを含み;ここで前記キメラ分子が腫瘍細胞と特異的に結合する方法。 2.前記標的指向分子がIL−13である請求の範囲1記載の方法。 3.前記標的指向分子が抗IL−13受容体抗体である請求の範囲1記載の方法。 4.前記標的指向分子が環状変更されたIL−13である請求の範囲1記載の方法 。 5.前記腫瘍が癌腫からなる群から選択される請求の範囲1記載の方法。 6.前記腫瘍が、腎臓細胞癌腫、神経膠腫、髄芽細胞腫、腎細胞癌腫およびカ ポージ肉腫からなる群から選択される請求の範囲1記載の方法。 7.前記エフェクター分子が、細胞毒素、標識、放射性核種、医薬、リポソー ム、リガンドおよび抗体からなる群から選択される請求の範囲1記載の方法。 8.前記エフェクター分子がシュードモナス外毒素である請求の範囲7記載の 方法。 9.キメラ分子が融合タンパク質である請求の範囲8記載の方法。 10.前記融合タンパク質がIL−13−PE38QQRである請求の範囲9 記載の方法。 11.前記融合タンパク質がcpIL−13−PE4Eである請求の範囲9記載の方法。 12.前記融合タンパク質がIL−13−PE4Eである請求の範囲9記載の方法。 13.前記融合タンパク質がcpIL−13−PE4Eである請求の範囲9記載の方法。 14.IL−13受容体を有する腫瘍細胞の増殖を阻害する方法であって; ヒトIL−13受容体と特異的に結合する標的指向分子;および 細胞毒、放射性核種、リガンドおよび抗体からなる群から選択されるエフェク ター分子、 を含むキメラ分子を前記腫瘍と接触させることを含み;ここで前記キメラ分子 が腫瘍細胞と特異的に結合する方法。 15.前記標的指向分子がヒトIL−13受容体と特異的に結合する抗体である請求 の範囲14記載の方法。 16.前記標的指向分子がヒトIL−13である請求の範囲14記載の方法。 17.前記標的指向分子が環状変更されたヒトIL−13である請求の範囲14記載の 方法。 18.前記エフェクター分子が細胞毒である請求の範囲16または17に記載の方法 。 19.前記細胞毒が、シュードモナス外毒素、リシン、アブリンおよびジフテリ ア毒素からなる群から選択される請求の範囲18記載の方法。 20.キメラ分子が一本鎖の融合タンパク質である請求の範囲19記載の方法。 21.前記細胞毒がシュードモナス外毒素である請求の範囲19記載の方法。 22.前記シュードモナス外毒素がPE38QQRである請求の範囲21記載の方法。 23.前記シュードモナス外毒素がPE4Eである請求の範囲21記載の方法。 24.前記腫瘍細胞の増殖がヒト内での腫瘍の増殖である請求の範囲16または17 に記載の方法。 25.前記接触が、前記キメラ分子を、ヒトに、静脈内投与するか、体腔内に投 与するかまたは内腔内もしくは器官内に投与することからなる請求の範囲24記載 の方法。 26.腫瘍の有無を検出する方法であって; ヒトIL−13受容体と特異的に結合する標的指向分子;および 検出可能な標識; を含むキメラ分子を前記腫瘍と接触させ; そして 前記標識の有無を検出する、 を含む方法。 27.ポリペプチドに結合されたIL−13または環状変更されたIL−13を含むキメ ラ融合タンパク質をコードする核酸配列を含むベクターであって;前記キメラ融 合タンパク質がIL−13受容体を有する腫瘍細胞に特異的に結合するベクター。 28.前記核酸配列がIL−13−PE融合タンパク質をコードする請求の範囲27記載 のベクター。 29.前記核酸配列がcpIL−13−PE融合タンパク質をコードする請求の範囲27記 載のベクター。 30.前記核酸配列が、IL−13−PE38QQR,cpIL−13−PE38QQR, IL−13−PE4EおよびcpIL−13−PE4Eからなる群から選択される融合タンパク質を コードする請求の範囲28または29に記載のベクター。 31.ポリペプチドに結合されたIL−13または環状変更IL−13を含んでなるキメ ラ融合タンパク質をコードする核酸配列を含んでなる宿主細胞であって;前記キ メラ融合タンパク質がIL−13受容体を有する腫瘍細胞に特異的に結合する宿主細 胞。 32.前記核酸配列がIL−13−PE融合タンパク質をコードする請求の範囲31記載 の宿主細胞。 33.前記核酸配列が、IL−13−PE38QQR,cpIL−13−PE38QQR,IL13−PE4Eおよ びcpIL−13PE4Eからなる群から選択される融合タンパク質をコードする請求の範 囲32記載のベクター。 34.IL−13受容体を有する腫瘍細胞と特異的に結合し、かつIL−13受容体と特 異的に結合する標的指向分子に結合された細胞毒分子を含んでなるキメラ分子。 35.前記標的指向分子がヒトIL−13である請求の範囲34に記載の組成物。 36.前記細胞毒が、シュードモナス外毒素、リシン、アブリンおよびジフテリ ア毒素からなる群から選択される請求の範囲34に記載の組成物。 37.キメラ分子が一本鎖の融合タンパク質である請求の範囲35記載の組成物。 38.前記細胞毒がシュードモナス外毒素である請求の範囲37記載の方法。 39.前記シュードモナス外毒素がPE38QQRまたはPE4Eである請求の範囲38,39 ,41または46に記載の組成物。 40.IL−13受容体を有する腫瘍細胞と特異的に結合し、かつIL−13受容体と特 異的に結合する抗体に結合されたエフェクター分子を 含んでなるキメラ分子。 41.前記エフェクター分子が、細胞毒、標識、放射性核種、医薬、リポソーム 、リガンドおよび抗体からなる群から選択される請求の範囲40記載の組成物。 42.医薬として許容される担体およびキメラ分子を含んでなる薬理学的組成物 であって;前記キメラ分子が、IL−13受容体に特異的に結合する標的指向分子に 結合されたエフェクター分子を含んでなる薬理学的組成物。 43.前記標的指向分子が、IL−13および環状変更されたIL−13からなる群から 選択される請求の範囲42記載の組成物。 44.前記エフェクター分子が細胞毒、標識、放射性核種、医薬、リポソーム、 リガンドおよび抗体からなる群から選択される請求の範囲43記載の組成物。 45.キメラ分子が一本鎖の融合タンパク質である請求の範囲44記載の組成物。 46.前記シュードモナス外毒素がPE38QQRまたはPE4Eである請求の範囲45記載 の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/404,685 US5614191A (en) | 1995-03-15 | 1995-03-15 | IL-13 receptor specific chimeric proteins and uses thereof |
US08/404,685 | 1995-03-15 | ||
PCT/US1996/003486 WO1996029417A1 (en) | 1995-03-15 | 1996-03-15 | Il-13 receptor specific chimeric proteins and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2000511042A true JP2000511042A (ja) | 2000-08-29 |
JP4202417B2 JP4202417B2 (ja) | 2008-12-24 |
Family
ID=23600619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52849996A Expired - Lifetime JP4202417B2 (ja) | 1995-03-15 | 1996-03-15 | Il−13受容体特異的キメラタンパク質およびその用途 |
Country Status (9)
Country | Link |
---|---|
US (2) | US5614191A (ja) |
EP (1) | EP1007696B1 (ja) |
JP (1) | JP4202417B2 (ja) |
AT (1) | ATE417931T1 (ja) |
AU (1) | AU714541B2 (ja) |
CA (1) | CA2215122A1 (ja) |
DE (1) | DE69637781D1 (ja) |
ES (1) | ES2319827T3 (ja) |
WO (1) | WO1996029417A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004507264A (ja) * | 2000-08-30 | 2004-03-11 | ザ ペン ステート リサーチ ファウンデーション | インターロイキン13のアミノ酸置換変異体 |
JP2005506960A (ja) * | 2001-06-07 | 2005-03-10 | ワイエス | Il−13の溶液構造およびこの使用 |
JP2005508375A (ja) * | 2001-11-09 | 2005-03-31 | ネオファーム、インコーポレイティッド | Il−13を発現する腫瘍の選択的治療 |
JP2006504623A (ja) * | 2002-03-22 | 2006-02-09 | アムラッド オペレイションズ ピーティーワイ リミティッド | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
JP2007516232A (ja) * | 2003-05-23 | 2007-06-21 | ジェネンテック・インコーポレーテッド | 膠細胞起源の腫瘍の診断と治療のための組成物と方法 |
WO2008146911A1 (ja) * | 2007-06-01 | 2008-12-04 | Sapporo Medical University | IL13Ra2に対する抗体およびこれを含む診断・治療薬 |
JP2018536434A (ja) * | 2015-10-30 | 2018-12-13 | アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. | 腫瘍形質導入のための組成物及び方法 |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010053371A1 (en) * | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US6518061B1 (en) | 1995-03-15 | 2003-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
US6428788B1 (en) | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
US6900304B2 (en) | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
US6803188B1 (en) * | 1996-01-31 | 2004-10-12 | The Regents Of The University Of California | Tandem fluorescent protein constructs |
CA2202103C (en) * | 1996-04-11 | 2007-01-09 | Toshiaki Tagawa | Method for preparing closed vesicles |
US5925558A (en) * | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5912137A (en) | 1996-07-16 | 1999-06-15 | The Regents Of The University Of California | Assays for protein kinases using fluorescent |
WO1998033914A1 (en) * | 1997-01-31 | 1998-08-06 | University Of Rochester | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US5998204A (en) * | 1997-03-14 | 1999-12-07 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
US6197928B1 (en) | 1997-03-14 | 2001-03-06 | The Regents Of The University Of California | Fluorescent protein sensors for detection of analytes |
DE19735105A1 (de) * | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
GB9725126D0 (en) * | 1997-11-27 | 1998-01-28 | Svanborg Catharina | Therapeutic agents |
US20030129132A1 (en) * | 1998-02-17 | 2003-07-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | IL-13 receptor specific chimeric proteins & uses thereof |
US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US6296843B1 (en) * | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
AU2007201759B2 (en) * | 1998-07-22 | 2008-05-29 | Osprey Pharmaceuticals Usa, Inc. | Conjugates for treating inflammatory disorders and associated tissue damage |
US6495664B1 (en) * | 1998-07-24 | 2002-12-17 | Aurora Biosciences Corporation | Fluorescent protein sensors of post-translational modifications |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
EP1222212A4 (en) * | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
US6346247B1 (en) | 1999-10-28 | 2002-02-12 | Promega Corporation | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
EP1263785A2 (en) * | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated il-13 molecules and their uses |
DE60131430T2 (de) * | 2000-01-14 | 2008-10-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
US20020197266A1 (en) * | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
AU2001253282A1 (en) * | 2000-04-07 | 2001-10-23 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
WO2002017968A2 (en) * | 2000-08-31 | 2002-03-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Sensitization of cancer cells to immunoconjugate-induced cell death by transfection with il-13 receptor alpha chain-2 |
DE10045592A1 (de) * | 2000-09-15 | 2002-03-28 | Klaus Pfizenmaier | Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie |
GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
JP3829252B2 (ja) * | 2001-06-08 | 2006-10-04 | 独立行政法人理化学研究所 | 蛍光蛋白質 |
US7666674B2 (en) * | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
AU2002361468A1 (en) | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
AU2002258011B2 (en) * | 2001-12-04 | 2009-01-08 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Chimeric molecule for the treatment of TH2-like cytokine mediated disorders |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
WO2003054161A2 (en) | 2001-12-20 | 2003-07-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
JP2005520539A (ja) * | 2002-03-19 | 2005-07-14 | ザ・ペン・ステート・リサーチ・ファンデーション | Egfrリガンドおよび使用方法 |
EP1496923A4 (en) * | 2002-03-22 | 2005-10-19 | Penn State Res Found | IMMUNOTHERAPY AGAINST CANCER |
EP1498137A1 (en) * | 2002-04-25 | 2005-01-19 | Chugai Seiyaku Kabushiki Kaisha | Remedy for lung cancer |
GB0210464D0 (en) | 2002-05-08 | 2002-06-12 | Svanborg Catharina | Therapeutic treatment |
GB0211658D0 (en) * | 2002-05-22 | 2002-07-03 | Svanborg Catharina | Novel therapies and methods of screening for therapeutic compounds |
CA2489540A1 (en) * | 2002-06-14 | 2003-12-31 | The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer | Methods of treating and preventing colitis involving il-13 and nk-t cells |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
WO2004087758A2 (en) * | 2003-03-26 | 2004-10-14 | Neopharm, Inc. | Il 13 receptor alpha 2 antibody and methods of use |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
US7619059B2 (en) * | 2003-07-29 | 2009-11-17 | Life Technologies Corporation | Bimolecular optical probes |
CA2445420A1 (en) * | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
US20050064485A1 (en) * | 2003-09-12 | 2005-03-24 | Kurt Vogel | Multiplex binding and activity assays |
EP1687016A4 (en) | 2003-11-25 | 2009-07-29 | Anjin Corp | GENETIC VARIANT OF DIPHTHERIC TOXIN |
JP2007522246A (ja) * | 2004-02-12 | 2007-08-09 | ネクター セラピューティクス | インターロイキン−13拮抗剤粉末剤、スプレードライ粒子、及び方法 |
WO2005091853A2 (en) * | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
DE602005025525D1 (de) | 2004-11-17 | 2011-02-03 | Amgen Inc | Vollständige humane monoklonale antikörper gegen il-13 |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
ES2412005T3 (es) | 2005-04-15 | 2013-07-09 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Tratamiento y prevención de la enfermedad intestinal inflamatoria que implica IL-13 y células NKT |
US20070160658A1 (en) * | 2005-10-20 | 2007-07-12 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
US8343461B2 (en) | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
WO2007103522A2 (en) | 2006-03-08 | 2007-09-13 | Wake Forest University Health Sciences | Soluble monomeric ephrin a1 |
EP2076285A4 (en) * | 2006-10-19 | 2010-06-30 | Merck Sharp & Dohme | ANTIBODY ANTAGONISTS OF THE INTERLEUKIN-13 RECEPTOR 1 |
MX2010005891A (es) | 2007-12-15 | 2010-06-09 | Hoffmann La Roche | Analisis diferenciador. |
WO2010121125A1 (en) | 2009-04-17 | 2010-10-21 | Wake Forest University Health Sciences | Il-13 receptor binding peptides |
US8362207B2 (en) | 2010-04-16 | 2013-01-29 | Wake Forest University Health Sciences | Multi-level specific targeting of cancer cells with IL-13 |
EP3401402B1 (en) | 2012-06-08 | 2020-10-14 | Alkermes Pharma Ireland Limited | Ligands modified by circular permutation as agonists and antagonists |
WO2015000865A1 (en) | 2013-07-04 | 2015-01-08 | F. Hoffmann-La Roche Ag | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
US9975942B2 (en) | 2013-11-11 | 2018-05-22 | Wake Forest University Health Services | EPHA3 And multi-valent targeting of tumors |
EP3368559A4 (en) | 2015-10-30 | 2020-01-15 | Aleta Biotherapeutics Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER |
US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
CA3120619A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082927A (en) * | 1986-09-24 | 1992-01-21 | The United States Of America As Represented By The Department Of Health And Human Services | Selectively cytotoxic IL-4-PE40 fusion protein |
EP0656947A1 (en) * | 1992-08-21 | 1995-06-14 | Schering Corporation | Human interleukin-13 |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
US5614191A (en) * | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
-
1995
- 1995-03-15 US US08/404,685 patent/US5614191A/en not_active Expired - Lifetime
-
1996
- 1996-03-15 ES ES96909693T patent/ES2319827T3/es not_active Expired - Lifetime
- 1996-03-15 JP JP52849996A patent/JP4202417B2/ja not_active Expired - Lifetime
- 1996-03-15 CA CA002215122A patent/CA2215122A1/en not_active Abandoned
- 1996-03-15 AU AU53110/96A patent/AU714541B2/en not_active Expired
- 1996-03-15 DE DE69637781T patent/DE69637781D1/de not_active Expired - Lifetime
- 1996-03-15 AT AT96909693T patent/ATE417931T1/de not_active IP Right Cessation
- 1996-03-15 WO PCT/US1996/003486 patent/WO1996029417A1/en active Application Filing
- 1996-03-15 EP EP96909693A patent/EP1007696B1/en not_active Expired - Lifetime
-
1997
- 1997-03-21 US US08/821,840 patent/US5919456A/en not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004507264A (ja) * | 2000-08-30 | 2004-03-11 | ザ ペン ステート リサーチ ファウンデーション | インターロイキン13のアミノ酸置換変異体 |
JP4863150B2 (ja) * | 2000-08-30 | 2012-01-25 | ザ・ペン・ステート・リサーチ・ファンデーション | インターロイキン13のアミノ酸置換変異体 |
JP2005506960A (ja) * | 2001-06-07 | 2005-03-10 | ワイエス | Il−13の溶液構造およびこの使用 |
JP2005508375A (ja) * | 2001-11-09 | 2005-03-31 | ネオファーム、インコーポレイティッド | Il−13を発現する腫瘍の選択的治療 |
JP2010031015A (ja) * | 2002-03-22 | 2010-02-12 | Zenyth Operations Pty Ltd | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
US7785590B2 (en) | 2002-03-22 | 2010-08-31 | Zenyth Operations Pty Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1) |
JP2006504623A (ja) * | 2002-03-22 | 2006-02-09 | アムラッド オペレイションズ ピーティーワイ リミティッド | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
US8221755B2 (en) | 2002-03-22 | 2012-07-17 | Zenyth Operations Pty Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ralpha1) |
JP2007516232A (ja) * | 2003-05-23 | 2007-06-21 | ジェネンテック・インコーポレーテッド | 膠細胞起源の腫瘍の診断と治療のための組成物と方法 |
JP4703567B2 (ja) * | 2003-05-23 | 2011-06-15 | ジェネンテック, インコーポレイテッド | 膠細胞起源の腫瘍の診断と治療のための組成物と方法 |
US8008004B2 (en) | 2003-05-23 | 2011-08-30 | Genentech Inc. | Compositions and methods for the diagnosis and treatment of tumors of glial origin |
WO2008146911A1 (ja) * | 2007-06-01 | 2008-12-04 | Sapporo Medical University | IL13Ra2に対する抗体およびこれを含む診断・治療薬 |
JP2018536434A (ja) * | 2015-10-30 | 2018-12-13 | アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. | 腫瘍形質導入のための組成物及び方法 |
US11059904B2 (en) | 2015-10-30 | 2021-07-13 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
Also Published As
Publication number | Publication date |
---|---|
EP1007696A1 (en) | 2000-06-14 |
ES2319827T3 (es) | 2009-05-12 |
JP4202417B2 (ja) | 2008-12-24 |
US5919456A (en) | 1999-07-06 |
AU5311096A (en) | 1996-10-08 |
ATE417931T1 (de) | 2009-01-15 |
WO1996029417A1 (en) | 1996-09-26 |
EP1007696B1 (en) | 2008-12-17 |
DE69637781D1 (de) | 2009-01-29 |
CA2215122A1 (en) | 1996-09-26 |
AU714541B2 (en) | 2000-01-06 |
US5614191A (en) | 1997-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000511042A (ja) | Il−13受容体特異的キメラタンパク質およびその用途 | |
US6428788B1 (en) | Compositions and methods for specifically targeting tumors | |
US6518061B1 (en) | IL-13 receptor specific chimeric proteins and uses thereof | |
CA2325341C (en) | Mutagenized il13-based chimeric molecules | |
US6576232B1 (en) | IL13 mutants | |
JP2005525115A (ja) | サイトカインと腫瘍標的指向蛋白質との融合 | |
JP4656937B2 (ja) | 腫瘍治療用の免疫複合体 | |
JP2003515567A (ja) | 腺維芽細胞成長受容体−3又は−2を発現する細胞を標的化するための方法 | |
IL183710A (en) | Conjugated product | |
AU2001288405B2 (en) | Amino acid substitution mutants of interleukin 13 | |
US6884603B2 (en) | Nucleic acids encoding IL13 mutants | |
CA2386248A1 (en) | Il13 mutants | |
US6630576B2 (en) | Amino acid substitution mutants of interleukin 13 | |
WO2008152508A2 (en) | Cytokine conjugate | |
US20030129132A1 (en) | IL-13 receptor specific chimeric proteins & uses thereof | |
JP2006514984A (ja) | 癌療法で用いる修飾されたサイトカイン | |
WO2020249757A1 (en) | Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha | |
EA042513B1 (ru) | Psma-нацеленные триспецифические белки и способы их применения | |
Wels et al. | Recombinant fusion toxins targeted to members of the ErbB family of receptor tyrosine kinases | |
AU2001288405A1 (en) | Amino acid substitution mutants of interleukin 13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060414 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080520 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080723 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080909 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081009 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111017 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121017 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131017 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |